Self-monitoring of blood glucose is now widely recognized as efficacious to enhance and facilitate diabetes management. More than just a means of recording and storing data, some blood glucose meters (BGMs) are now designed with an embedded automated bolus calculator (ABC) with the goal to propose patients recommendations about insulin dosage. The growing literature in this field tends to claim that these new smart BGMs make patient's life easier and decision making safer. The main purpose of this review is to verify whether BGMs with a built-in ABC indeed improve the willingness and the ability of insulin-treated patients to make adequate therapeutic decisions and positively impact the metabolic control and the quality of life of ABC users. It appears that, as long as the education provided by caregivers remains a top priority, BGMs with a built-in ABC (more than just electronic gadgets) can be regarded as bringing real value to insulintreated patients with diabetes.
INTRODUCTION
Evidence accumulated over past decades convincingly demonstrates that adequate and sustainable metabolic control in people with diabetes results in better micro-and macrovascular outcomes [1] [2] [3] [4] [5] [6] . In addition, when this control occurs early on, it may evidence indicates that regular assessment of blood glucose (BG) levels may help insulintreated patients to achieve better glycemic control. Self-monitoring of BG (SMBG) contributes to better adjustment of therapies, and helps to reach treat-to-target goals. More importantly, SMBG can act as an educational tool to support patients to better adhere to their treatment [8] [9] [10] [11] [12] [13] [14] [15] [16] . SMBG may provide fruitful feedback about how nutrition therapy, physical activity, and medications influence BG levels and alerts about hypo-and hyperglycemia [15] .
However, some patients are reluctant to use SMBG due to the pain associated with finger sticks and the cost associated with SMBG supplies. Additionally, some patients are unable to interpret SMBG data and translate it into appropriate therapeutic decisions [15] .
One way to improve SMBG acceptance is to provide therapy algorithms to support patients 
METHODS
The question raised in this review is whether BG meters (BGMs) with a built-in automated bolus calculator (ABC) represent an added value in patient performance and ability to make the right therapeutic decisions, which may impact both metabolic control and quality of life. A literature search was carried out using Medline and PubMed to select papers where an ABC was used in addition to SMBG. The papers quoted in this review were selected to bring insights into specific questions concerning improved capability of patients to make therapeutic decisions, treatment satisfaction, improved metabolic control and decreased glycemic variability, and reduced fear and rate of hypoglycemia.
Premeal Short-Acting Insulin Dose Calculations
For SMBG to be considered useful, it should be used regularly and correctly at the very least. provided by control solutions, to manually calculate mealtime doses of short-acting insulin, followed by the same calculation using a glucose meter with a built-in ABC [29] .
Two cohorts of patients, either carbohydrate counters (n = 101) who were using a sophisticated formula, or noncarbohydrate counters (n = 104) who were using a simplified formula, were considered for the study. The results showed that 63% of doses calculated manually by the participants were erroneous, whereas only 6% of incorrect responses were recorded when calculations were performed with an ABC. Eighty-three percent of subjects felt confident about using the ABC and 87% preferred the automated method to the manual calculation. The study was not designed to evaluate the direct impact of ABCs on metabolic control, as the testing was based on control solution values, not on actual blood tests [29] .
These results are in line with several previous studies that showed only a small proportion of people with diabetes able to adequately calculate insulin doses, while taking into account glucose load and BG levels. This may explain the low level of treatment compliance and therapeutic inertia over the long duration Diabetes Ther (2013) 4:1-11 3
of diabetes [24, 30, 31] . These data are also reminiscent of those from a 2008 study that demonstrated a benefit of using an ABC in a pediatric population of CSII-treated patients, both in terms of personal satisfaction and improved preprandial and 2-h postprandial BG levels [32] . In one older study [31] , an improvement in treatment satisfaction, adherence, and quality of life was shown in 83 adolescents using MDI or CSII. Another study with 49 CSII-treated patients [33] reported better postprandial BG excursions and good confidence in the doses advised by the device (Table 1 [29, [31] [32] [33] [37] .
In a small study (n = 18) published in 2008 comparing ABC users to nonusers, improved metabolic control did not occur [34] . Although mean postprandial BG levels in the ABC users were significantly lowered compared to nonusers, HbA 1c values were not significantly improved [38] . Noteworthy, this was an observational study, not a randomized study.
Furthermore, the decision whether to use the ABC or not was left to the patient's discretion.
Two other quite recent studies in CSII-treated young type 1 diabetic patients reached the same conclusion. There was an improvement in 2-h postprandial BG levels and glucose variability, but no significant improvement of HbA 1c values [39, 40] . The discrepancies between these studies can be understood considering differences in study design and duration (Table 2 [ 
34-40]).
Are There Other Advantages to Using BGMs with Built-In ABCs?
Another relevant advantage of using an ABC, besides easier bolus calculation and the likely improvement in metabolic control, or at least in glucose variability, is the reduction in fear and rate of hypoglycemia. This was shown in a recent study that surveyed 1,412 MDI-treated type 1 diabetes patients, of which 588 responded positively [41] . The vast majority of them (76.7%) claimed to use the ABC quite often or always. In 52% of respondents, the fear of hypoglycemia was reduced and most of them (78.8%) reported a high confidence in the insulin dose calculation. In addition, 89.3% reported that bolus calculation was made easy or very easy when the bolus advisor was used. Although Even though data are contradictory about hypoglycemic events, with at least one study reporting more severe hypoglycemia among ABC users [36] , a recent study by Bergenstal et al. [42] , where an insulin support decision algorithm was tested both in subjects with type 1 and type 2 diabetes, rather supports the idea that the frequency of hypoglycemia is lower among patients using an ABC. Thus, less hypoglycemic episodes occurred in the groups using the algorithm despite the higher rate of insulin adjustment. Another important piece of information brought forward by this paper is related to the fact that besides subjects with type 1 diabetes, two groups of subjects with type 2 diabetes (treated either with basal-bolus therapy or twice-daily biphasic insulin) also appeared to show benefit from the computer decision system. This indicates that smart BGMs should not be reserved only for subjects with type 1 diabetes, but rather offered to all MDItreated patients, regardless of the type of diabetes (Table 3 [41, 42] ).
DISCUSSION
Although a consensus is emerging that SMBG increases awareness of diabetes, as well as patient's empowerment and reassurance, there are also papers reporting worsened quality of life among patients using the SMBG method.
Of note, these studies were performed with type 2 diabetes patients who reported increased anxiety and depression, and even obsessive behaviour [43] [44] [45] [46] [47] . These feelings were often associated with HCPs lack of interest to actively check and use SMBG results that were otherwise carefully collected by patients. This highlights the pivotal educational role of HCPs about the importance they bring to the interpretation of improved HbA 1c and a reduced rate of diabetes complications [13] . Regular assessments must be foreseen to make sure that recommendations provided by the system are done in a safe way and always in close connection with the patient needs. As long as the principle of ongoing education is The reduced risk of hypoglycemia is certainly another relevant advantage of BGMs with built-in ABCs. The fear of hypoglycemia, just as a low level of education, often precludes the ability of patients to make changes and is a source of therapeutic inertia. Hypoglycemia is one of the main causes of alteration of the patient's quality of life. The ongoing technical improvements and, for instance, the recent progresses in telemedicine should make us more confident in the ability of support decision software to alert patients in real time about hypoglycemia [48] . This is of course crucial as, most of the time, actual systems do not warn enough patients about hypoglycemia and about the importance of managing it before injecting the next dose of insulin. In addition, they should also encourage patients to inject insulin as soon as BG levels are getting back to normal, a requirement that is often neglected by patients when recovering from hypoglycemia. 
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